Haemonetics Corporation (NYSE:HAE) is listed as one of the 13 Oversold Value Stocks to Invest in Now. Mizuho recently reduced its price target on HAE from $90 to $70 following the company’s fiscal Q1 results. Despite reporting a $20 million revenue beat and strong performance in Plasma and Blood Center, concerns over slowing growth in the VASCADE MVP product line led to a 26% share price decline. Mizuho highlighted leadership strategy shifts and competitive pressures as key concerns, expecting recovery to take at least six months. Haemonetics Corporation is a global medical technology firm specializing in plasma collection systems and advanced hospital solutions. While FICO shows investment potential, certain AI stocks offer greater upside potential with less downside risk. For more insights on the best short-term AI stock, check out our free report.

Read more at Yahoo Finance: Mizuho Reduces PT on Haemonetics Corporation (HAE) Following Fiscal Q1 2025 Results